1. Home
  2. ORGO vs TTRX Comparison

ORGO vs TTRX Comparison

Compare ORGO & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Organogenesis Holdings Inc.

ORGO

Organogenesis Holdings Inc.

HOLD

Current Price

$1.81

Market Cap

239.3M

Sector

Health Care

ML Signal

HOLD

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$9.90

Market Cap

281.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORGO
TTRX
Founded
1985
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
239.3M
281.2M
IPO Year
2016
2025

Fundamental Metrics

Financial Performance
Metric
ORGO
TTRX
Price
$1.81
$9.90
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$8.50
$8.00
AVG Volume (30 Days)
878.3K
70.7K
Earning Date
05-07-2026
05-31-2026
Dividend Yield
N/A
N/A
EPS Growth
1600.00
N/A
EPS
N/A
N/A
Revenue
$564,169,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$26.27
N/A
P/E Ratio
N/A
N/A
Revenue Growth
17.04
N/A
52 Week Low
$1.54
$2.57
52 Week High
$7.08
$11.69

Technical Indicators

Market Signals
Indicator
ORGO
TTRX
Relative Strength Index (RSI) 28.03 56.29
Support Level $1.54 $2.95
Resistance Level $2.64 $10.48
Average True Range (ATR) 0.13 0.85
MACD -0.07 0.02
Stochastic Oscillator 23.00 68.38

Price Performance

Historical Comparison
ORGO
TTRX

About ORGO Organogenesis Holdings Inc.

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: